JP2022512757A - 3d堆積用バイオインク - Google Patents
3d堆積用バイオインク Download PDFInfo
- Publication number
- JP2022512757A JP2022512757A JP2021521336A JP2021521336A JP2022512757A JP 2022512757 A JP2022512757 A JP 2022512757A JP 2021521336 A JP2021521336 A JP 2021521336A JP 2021521336 A JP2021521336 A JP 2021521336A JP 2022512757 A JP2022512757 A JP 2022512757A
- Authority
- JP
- Japan
- Prior art keywords
- bioink
- hchamp
- volume
- differentiation
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008021 deposition Effects 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 103
- 210000004413 cardiac myocyte Anatomy 0.000 claims abstract description 95
- 230000004069 differentiation Effects 0.000 claims abstract description 69
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims abstract description 62
- 108010010803 Gelatin Proteins 0.000 claims abstract description 48
- 239000008273 gelatin Substances 0.000 claims abstract description 48
- 229920000159 gelatin Polymers 0.000 claims abstract description 48
- 235000019322 gelatine Nutrition 0.000 claims abstract description 48
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 48
- 238000007639 printing Methods 0.000 claims abstract description 41
- 102000008186 Collagen Human genes 0.000 claims abstract description 33
- 108010035532 Collagen Proteins 0.000 claims abstract description 33
- 229920001436 collagen Polymers 0.000 claims abstract description 33
- JUYQFRXNMVWASF-UHFFFAOYSA-M lithium;phenyl-(2,4,6-trimethylbenzoyl)phosphinate Chemical compound [Li+].CC1=CC(C)=CC(C)=C1C(=O)P([O-])(=O)C1=CC=CC=C1 JUYQFRXNMVWASF-UHFFFAOYSA-M 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 99
- 238000000034 method Methods 0.000 claims description 70
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- 102000016359 Fibronectins Human genes 0.000 claims description 48
- 108010067306 Fibronectins Proteins 0.000 claims description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 31
- 230000002107 myocardial effect Effects 0.000 claims description 12
- 102000015735 Beta-catenin Human genes 0.000 claims description 11
- 108060000903 Beta-catenin Proteins 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 10
- 102000006312 Cyclin D2 Human genes 0.000 claims description 7
- 108010058544 Cyclin D2 Proteins 0.000 claims description 7
- 229910003002 lithium salt Inorganic materials 0.000 claims description 7
- 159000000002 lithium salts Chemical class 0.000 claims description 7
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 6
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- JZDGWLGMEGSUGH-UHFFFAOYSA-N phenyl-(2,4,6-trimethylbenzoyl)phosphinic acid Chemical compound CC1=CC(C)=CC(C)=C1C(=O)P(O)(=O)C1=CC=CC=C1 JZDGWLGMEGSUGH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- SYJCUYXTMQSJLM-UHFFFAOYSA-N phenylphosphanyl-(2,4,6-trimethylphenyl)methanone Chemical compound CC1=CC(C)=CC(C)=C1C(=O)PC1=CC=CC=C1 SYJCUYXTMQSJLM-UHFFFAOYSA-N 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 45
- 238000010586 diagram Methods 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 description 47
- 239000000976 ink Substances 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 46
- 230000000747 cardiac effect Effects 0.000 description 36
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 35
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 35
- 108010085895 Laminin Proteins 0.000 description 34
- 210000002744 extracellular matrix Anatomy 0.000 description 28
- 230000006870 function Effects 0.000 description 28
- 239000002609 medium Substances 0.000 description 25
- 210000005003 heart tissue Anatomy 0.000 description 24
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 22
- 229940039009 isoproterenol Drugs 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 19
- 239000011575 calcium Substances 0.000 description 19
- 229910052791 calcium Inorganic materials 0.000 description 19
- 230000035800 maturation Effects 0.000 description 19
- 238000002595 magnetic resonance imaging Methods 0.000 description 17
- 238000010146 3D printing Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 239000000975 dye Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000010412 perfusion Effects 0.000 description 12
- 239000011435 rock Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000024245 cell differentiation Effects 0.000 description 11
- 230000008602 contraction Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 10
- 238000000151 deposition Methods 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000000541 pulsatile effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 9
- 102000013814 Wnt Human genes 0.000 description 9
- 108050003627 Wnt Proteins 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 9
- 108010044426 integrins Proteins 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- -1 Lithium trimethylbenzoylphosphinic acid salt Chemical compound 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 210000003716 mesoderm Anatomy 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000007634 remodeling Methods 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000036982 action potential Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940001447 lactate Drugs 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000008093 supporting effect Effects 0.000 description 6
- 239000012583 B-27 Supplement Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 102000001045 Connexin 43 Human genes 0.000 description 4
- 108010069241 Connexin 43 Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 102000004987 Troponin T Human genes 0.000 description 4
- 108090001108 Troponin T Proteins 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 108010059517 integrin-linked kinase Proteins 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000010349 pulsation Effects 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000003255 drug test Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000012803 optimization experiment Methods 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002336 repolarization Effects 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102000010825 Actinin Human genes 0.000 description 2
- 108010063503 Actinin Proteins 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000001054 cardiac fibroblast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 210000002458 fetal heart Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 210000001650 focal adhesion Anatomy 0.000 description 2
- 239000000576 food coloring agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001057 ionotropic effect Effects 0.000 description 2
- 108010038862 laminin 10 Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004457 myocytus nodalis Anatomy 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002186 photoactivation Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SXZQQUBQEGDZJY-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;calcium Chemical compound [Ca].OC(=O)[C@@H](N)CC1=CC=CC=C1 SXZQQUBQEGDZJY-QRPNPIFTSA-N 0.000 description 1
- HAPJROQJVSPKCJ-UHFFFAOYSA-N 3-[4-[2-[6-(dibutylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCC)CCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 HAPJROQJVSPKCJ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 1
- 101710109123 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000003847 mesoderm development Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
- B33Y70/10—Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ceramic Engineering (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Structural Engineering (AREA)
- Composite Materials (AREA)
- Molecular Biology (AREA)
Abstract
Description
本発明は、国立衛生研究所(NIH)によって付与されたHL137204の下で政府の支援を受けて成された。政府は本発明に関して一定の権利を有する。
本開示は、構造体の三次元(3D)印刷に用いることができるバイオインク用の組成物を記載する。心臓組織工学の目標は、生理学的および解剖学的構造の理解を助けるインビトロ(in vitro)モデルシステムを作製することである。例えば、症状を緩和しかつ生存能力のアウトプットを改善する治療薬を創製するために、発達、成長および疾患に関して心臓をより詳細に理解することが望ましい場合がある。当該分野は、多能性幹細胞を効率的に利用して高効率で全ての心細胞型を誘導し、典型的にはヒトの筋肉を模倣した、可撓性基板(フレキシブルポスト)により担持されたマイクロスケールの組織片の形をとっている、しばしば「ミクロ組織」と称されるモデル系の開発へと移行した。このような組織片は、医薬品産業への恩恵を伴う薬物の試験に非常に有望であるが、組織片はまた、心室のような構造体のアーキテクチャと機能性出力を正確に再現する能力を欠いている。これは、組織の性能を動物またはヒトの心臓の性能と直接比較することは不可能であり、そのような性能は心室の圧力と容積の変化を測定することによって評価できるために、重大な制限因子である。さらに、疾患を伴う心臓のリモデリングは、複雑な流動プロファイルと、関連する心室に加わる力の刺激とその応答により、実質的に影響を受ける。
Claims (15)
- ゼラチンメタクリレートとコラーゲンメタクリレートとを含むバイオインク組成物。
- フェニル-2,4,6-トリメチルベンゾイルホスフィン酸リチウム塩をさらに含む、請求項1に記載のバイオインク組成物。
- mTeSR培地;酢酸;および水酸化ナトリウム(NaOH)を含む溶媒をさらに含む、請求項2に記載のバイオインク組成物。
- 前記溶媒が74重量/容積%のmTeSR 培地;20重量/容積%の20 mM酢酸;および1重量/容積%の1M NaOHを含む、請求項3に記載のバイオインク組成物。
- 前記バイオインク組成物が、約10重量/容積%のゼラチンメタクリレート;約0.25重量/容積%のコラーゲンメタクリレート;および約0.5重量/容積%のフェニル-2,4,6-トリメチルベンゾイルホスフィン酸リチウム塩を含む、請求項1~4のいずれか一項に記載のバイオインク組成物。
- フィブロネクチンまたはラミニンの少なくとも1つをさらに含む、請求項1~5のいずれか一項に記載のバイオインク組成物。
- 前記組成物が、約100ミリグラム/ミリリットル(mg/mL)のコラーゲンメタクリレート;約2.5 mg/mLのゼラチンメタクリレート;約5 mg/mLのフェニル-2,4,6-トリメチルベンゾイルホスフィン酸リチウム塩;約93.8マイクログラム/ミリリットル(μg/mL)のフィブロネクチン;および93.8μg/mLのラミニンを含む、請求項1~6のいずれか一項に記載のバイオインク組成物。
- ヒト人工多能性幹細胞をさらに含む、請求項1~7のいずれか一項に記載のバイオインク組成物。
- 前記ヒト人工多能性幹細胞が、ミオシン重鎖(MHC)のもとでサイクリンD2(CCND2)を過剰発現するヒト心臓線維芽細胞由来の人工多能性幹細胞を含む、請求項8のバイオインク組成物。
- 前記ヒト人工多能性幹細胞が心筋細胞前駆体を含む、請求項8のバイオインク組成物。
- 心筋細胞をさらに含む、請求項1~10のいずれか一項のバイオインク組成物。
- 前記バイオインク組成物が、心筋細胞へのヒト人工多能性幹細胞の分化を促進するように構成される、請求項1~11のいずれか一項に記載のバイオインク組成物。
- 請求項1~12のいずれか一項のバイオインク組成物を使って三次元構造体を印刷することを含む方法。
- 請求項1~12のいずれか一項のバイオインク組成物を使って三次元構造体を印刷することが、前記バイオインクを使って三次元構造体を印刷して少なくとも1つの室を構築することを含む、請求項13の方法。
- 前記三次元構造体が、ヒト人工多能性幹細胞を含み、そして前記方法が、小分子でWnt/β-カテニン経路を調節することによりヒト人工多能性幹細胞を心筋細胞へと分化するように誘導することをさらに含む、請求項13~14のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862747490P | 2018-10-18 | 2018-10-18 | |
US62/747,490 | 2018-10-18 | ||
PCT/US2019/057009 WO2020081982A1 (en) | 2018-10-18 | 2019-10-18 | Bioink for 3d deposition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512757A true JP2022512757A (ja) | 2022-02-07 |
JP7384453B2 JP7384453B2 (ja) | 2023-11-21 |
Family
ID=68468857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021521336A Active JP7384453B2 (ja) | 2018-10-18 | 2019-10-18 | 3d堆積用バイオインク |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220031848A1 (ja) |
EP (1) | EP3866763A1 (ja) |
JP (1) | JP7384453B2 (ja) |
CA (1) | CA3116884C (ja) |
WO (1) | WO2020081982A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111388750B (zh) * | 2020-04-30 | 2022-09-13 | 深圳先进技术研究院 | 生物墨水、小口径管状结构支架及其制备方法和应用 |
US20220016419A1 (en) * | 2020-07-16 | 2022-01-20 | Biosense Webster (Israel) Ltd. | Apparatus for testing a cardiac catheter utilizing live cardiac cells |
US11918703B2 (en) * | 2020-08-13 | 2024-03-05 | Universidad De Los Andes | Extrudable photocrosslinkable hydrogel and method for its preparation |
WO2022073090A1 (pt) | 2020-10-06 | 2022-04-14 | Janaina De Andrea Dernowsek Ltda | Método para a produção de uma composição de proteínas de matriz extracelular e produto obtido por tal método |
KR102475487B1 (ko) * | 2020-10-12 | 2022-12-08 | 고려대학교 산학협력단 | 심장 이식용 시트 및 이의 제조방법 |
CN112852724B (zh) * | 2021-01-05 | 2022-09-06 | 首玺(广州)医疗科技有限责任公司 | 一种含干细胞活性因子的美容组合物及其制备方法和应用 |
WO2022261534A2 (en) * | 2021-06-11 | 2022-12-15 | University Of Maryland, Baltimore | Three-dimensional cell-laden bioink scaffolds and methods of making the same under cryogenic conditions for tissue engineering |
CN113750292B (zh) * | 2021-09-30 | 2022-10-25 | 华南理工大学 | 一种用于3d打印角膜修复材料的生物墨水及制备方法、角膜修复材料的制备方法 |
CN114870093B (zh) * | 2022-05-07 | 2023-04-07 | 四川大学 | 基于数字光处理的3d打印组织工程胰岛及其制备方法和用途 |
WO2023228255A1 (ja) * | 2022-05-23 | 2023-11-30 | 学校法人早稲田大学 | 筒状臓器関連病変モデルおよびその製造方法など |
PT118047A (pt) | 2022-06-15 | 2023-12-15 | Univ Aveiro | Composição para manufatura aditiva constituida por um hidrogel compósito, processo de produção da dita composição, e processo de manufatura aditiva de um objeto usando a dita composição |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017101015A (ja) * | 2015-11-25 | 2017-06-08 | 株式会社サイフューズ | ヒト心臓様構造体およびその製造方法 |
WO2017214592A1 (en) * | 2016-06-09 | 2017-12-14 | Paul Gatenholm | Preparation of modified cellulose nanofibrils with extracellular matrix components as 3d bioprinting bioinks |
WO2018071639A1 (en) * | 2016-10-12 | 2018-04-19 | Advanced Biomatrix, Inc. | Three-dimensional (3-d) printing inks made from natural extracellular matrix molecules |
WO2018078130A1 (en) * | 2016-10-28 | 2018-05-03 | Paul Gatenholm | Preparation and applications of 3d bioprinting bioinks for repair of bone defects, based on cellulose nanofibrils hydrogels with natural or synthetic calcium phosphate particles |
WO2018181342A1 (ja) * | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 未分化維持培地添加剤 |
-
2019
- 2019-10-18 JP JP2021521336A patent/JP7384453B2/ja active Active
- 2019-10-18 EP EP19798479.2A patent/EP3866763A1/en active Pending
- 2019-10-18 US US17/309,037 patent/US20220031848A1/en active Pending
- 2019-10-18 WO PCT/US2019/057009 patent/WO2020081982A1/en unknown
- 2019-10-18 CA CA3116884A patent/CA3116884C/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017101015A (ja) * | 2015-11-25 | 2017-06-08 | 株式会社サイフューズ | ヒト心臓様構造体およびその製造方法 |
WO2017214592A1 (en) * | 2016-06-09 | 2017-12-14 | Paul Gatenholm | Preparation of modified cellulose nanofibrils with extracellular matrix components as 3d bioprinting bioinks |
WO2018071639A1 (en) * | 2016-10-12 | 2018-04-19 | Advanced Biomatrix, Inc. | Three-dimensional (3-d) printing inks made from natural extracellular matrix molecules |
WO2018078130A1 (en) * | 2016-10-28 | 2018-05-03 | Paul Gatenholm | Preparation and applications of 3d bioprinting bioinks for repair of bone defects, based on cellulose nanofibrils hydrogels with natural or synthetic calcium phosphate particles |
WO2018181342A1 (ja) * | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 未分化維持培地添加剤 |
Non-Patent Citations (2)
Title |
---|
JUN YIN ET AL., ACS APPL. MATER. INTERFACES, vol. 10, JPN6022024607, 6 February 2018 (2018-02-06), pages 6849 - 6857, ISSN: 0004804817 * |
久保田 晃史 他: "P−03−045 3Dプリント装置を用いたiPS由来三次元心筋組織体の調製と機能評価", 第17回日本再生医療学会総会プログラム・抄録, JPN6022024606, 23 March 2018 (2018-03-23), pages 81, ISSN: 0005022550 * |
Also Published As
Publication number | Publication date |
---|---|
EP3866763A1 (en) | 2021-08-25 |
WO2020081982A1 (en) | 2020-04-23 |
JP7384453B2 (ja) | 2023-11-21 |
CA3116884C (en) | 2023-10-17 |
US20220031848A1 (en) | 2022-02-03 |
CA3116884A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7384453B2 (ja) | 3d堆積用バイオインク | |
US20210348095A1 (en) | Systems and methods for immobilizing extracellular matrix material on organ on chip, multilayer microfluidics microdevices, and three-dimensional cell culture systems | |
Lesman et al. | Transplantation of a tissue-engineered human vascularized cardiac muscle | |
Maidhof et al. | Biomimetic perfusion and electrical stimulation applied in concert improved the assembly of engineered cardiac tissue | |
Kurokawa et al. | Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening | |
Lee et al. | Engineered cardiac organoid chambers: toward a functional biological model ventricle | |
US11890395B2 (en) | Three dimensional tissue compositions and methods of use | |
US10183097B2 (en) | Engineered cardiac derived compositions and methods of use | |
Cimetta et al. | Bioengineering heart tissue for in vitro testing | |
Atmanli et al. | Recreating the cardiac microenvironment in pluripotent stem cell models of human physiology and disease | |
Napiwocki et al. | Micropattern platform promotes extracellular matrix remodeling by human PSC‐derived cardiac fibroblasts and enhances contractility of co‐cultured cardiomyocytes | |
Mohamed et al. | Establishing the framework for tissue engineered heart pumps | |
US20230087578A1 (en) | Device and methods for engineering 3d complex tissues | |
US20240131225A1 (en) | Three dimensional tissue compositions and methods of use | |
Williams | Engineering 3D Human Cardiac Ventricular Models with Controllable Architecture | |
Lin | Extracellular Matrix-Based Microfabrication to Generate Advanced Models of Human Tissue Function | |
Magnussen | Engineering cardiogenesis | |
Riemenschneider | Development of Pre-Vascularized Tissues Containing Aligned and Perfusable Microvessels | |
Batalov | Engineering 2D Cardiac Tissues Using Biomimetic Protein Micropatterns Based on the Extracellular Matrix in the Embryonic Heart | |
Kupfer | 3D Printing to Recapitulate Cardiac Tissue Development, Structure, and Function | |
Jones | Three-Dimensional Collagen Tubes for in vitro Modeling | |
Du et al. | Progress of organoid platform in cardiovascular research | |
Strobel et al. | Isolated Fragments of Intact Microvessels: Tissue Vascularization, Modeling, and Therapeutics | |
Ahrens | Programming Complex Alignment in Engineered Cardiac Tissue | |
Aubin et al. | Whole-Heart Tissue Engineering: Use of Three-Dimensional Matrix Scaffolds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230728 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7384453 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |